Estrogen therapy increases benign breast disease risk

Women who took conjugated equine estrogen, a commonly prescribed form of estrogen, had more than twice the risk of developing specific types of benign breast disease as women who took a placebo, according to a randomized controlled trial published online April 8 in the Journal of the National Cancer Institute.

The impact of conjugated equine estrogen on the risk of developing benign proliferative breast disease, a condition that is associated with increased risk of breast cancer, has been unclear. Some studies have reported an association while others have not. In the Women's Health Initiative study, 10,739 postmenopausal women with hysterectomy were assigned to either conjugated equine estrogen or a placebo. Previous analyses did not show an increase in breast cancer incidence in the women who took estrogen alone after a median follow-up of seven years.

To determine whether the hormone increases the risk of benign proliferative breast disease, Tom Rohan, M.D., Ph.D., of the Albert Einstein College of Medicine in New York and colleagues identified and examined non-cancerous breast biopsies in each of the Women's Health Initiative trial arms.

A total of 232 cases of benign proliferative breast disease were identified, with 155 cases among the women who took estrogen supplements and 77 in the placebo group. The risk of developing benign disease increased by more than two-fold for women taking conjugated equine estrogen, compared with those taking a placebo.

“The prevailing hypothesis concerning the natural history of breast cancer is that benign proliferative breast disease without atypia, proliferative disease with atypia, and in situ cancer represent successive steps preceding the development of invasive breast [cancer]. In keeping with this hypothesis, women with benign proliferative breast disease have an increased risk of subsequent breast cancer,” the authors write.

Although the women taking conjugated equine estrogen have not yet shown a significant increased risk of breast cancer in the Women's Health Initiative study, if this hypothesis holds true, they might show increased risk later. Ongoing follow up of the study participants may help to resolve this issue.

Source: Journal of the National Cancer Institute

Related stories:

Vitamin D's wild days: Who to test, what to take?
(AP) -- Don't be surprised if your doctor orders a vitamin D test during your next physical. Blood tests to check levels of the so-called sunshine vitamin are on the rise as doctors and patients react to headline-grabbing research that suggests having too little may not only hurt your bones - it might increase your risk of certain cancers or heart disease.
Risk assessment plays key role in long-term treatment of breast cancer
Breast cancer patients and their physicians may make more informed, long-term treatment decisions using risk assessment strategies to help determine probability of recurrence, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reported in the Aug. 12 online issue of the Journal of the National Cancer Institute.
Improved estrogen reception may sharpen fuzzy memory
Estrogen treatments may sharpen mental performance in women with certain medical conditions, but University of Florida researchers suggest that recharging a naturally occurring estrogen receptor in the brain may also clear cognitive cobwebs.
Researchers identify cancer preventive properties in common vitamin supplement
Early laboratory research has shown that resveratrol, a common dietary supplement, suppresses the abnormal cell formation that leads to most types of breast cancer, suggesting a potential role for the agent in breast cancer prevention. Resveratrol is a natural substance found in red wine and red grapes. It is sold in extract form as a dietary supplement at most major drug stores.
Treatment delays result in poor outcomes for men with breast cancer
Men who develop breast cancer are often not treated until the disease has spread to the point that treatment becomes difficult, new results show.
Red wine's resveratrol may help battle obesity
Resveratrol, a compound present in grapes and red wine, reduces the number of fat cells and may one day be used to treat or prevent obesity, according to a new study. The results will be presented at The Endocrine Society's 90th Annual Meeting in San Francisco.
Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women
New analysis of a drug approved for osteoporosis prevention and treatment has provided definitive evidence that the medication is also effective as a breast cancer preventative for certain cancers. Women who took the drug raloxifene were less likely to develop invasive, estrogen-receptor (ER) positive breast cancer compared with women who did not take the drug. The results of the randomized controlled trial will be published in the June 10 online issue of the Journal of the National Cancer Institute.
Videos offer tips on reducing breast-cancer risk
Using certain plastics and cosmetics may increase the risk of breast cancer, according to emerging scientific research cited by Cornell investigators. Drinking from hard-plastic water bottles and using such personal-care products and cosmetics as shampoo, lotion and lipstick that contain certain chemicals can increase exposure to environmental estrogens that may contribute to breast-cancer risk.

News discussion:

Medicine & Health news